Challenges for Optimizing Real-World Evidence in Alzheimer’s Disease: The ROADMAP Project

Catherine Sudlow, John Gallacher, Frederic de Reydet de Vulpillieres, Billy Amzal, Zuzanna Angehrn, Christin Bexelius, Johan van der Lei, Pieter Jelle Visser, Andrew Turner, Christophe Bintener, Jacoline C Bouvy, Laura Campo, Carlos Diaz, Jean Georges, Alastair Gray, Antje Hottgenroth, Pall Jonsson Jonsson, Brent Mittelstadt, Michele H Potashman, Catherine ReedRobin Thompson, Antje Tockhorn-Heidenreich

Research output: Contribution to journalArticlepeer-review

Abstract

ROADMAP is a public-private advisory partnership to evaluate the usability of multiple data sources, including real-world evidence, in the decision-making process for new treatments in Alzheimer's disease, and to advance key concepts in disease and pharmacoeconomic modeling. ROADMAP identified key disease and patient outcomes for stakeholders to make informed funding and treatment decisions, provided advice on data integration methods and standards, and developed conceptual cost-effectiveness and disease models designed in part to assess whether early treatment provides long-term benefit.
Original languageEnglish
JournalJournal of Alzheimer's Disease
Early online date15 Dec 2018
DOIs
Publication statusE-pub ahead of print - 15 Dec 2018

Fingerprint

Dive into the research topics of 'Challenges for Optimizing Real-World Evidence in Alzheimer’s Disease: The ROADMAP Project'. Together they form a unique fingerprint.

Cite this